# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2021

# **Aesther Healthcare Acquisition Corp.**

(Exact name of registrant as specified in its charter)

Delaware	001-40793	87-1309280
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification Number)
515 Madison Avenue, Suite 8078		
New York, New York		10022
(Address of principal executive offices	)	(Zip Code)
Registrant's t	elephone number, including area code: <b>(646)</b> \$	008-2658
Check the appropriate box below if the Form 8-K filin following provisions (see General Instruction A.2. below		filing obligation of the registrant under any of the
☐ Written communications pursuant to Rule 425 under	the Securities Act (17 CFR 230.425)	
☐ Soliciting material pursuant to Rule 14a-12 under the	e Exchange Act (17 CFR 240.14a-12)	
☐ Pre-commencement communications pursuant to Ru	le 14d-2(b) under the Exchange Act (17 CFR 2	240.14d-2(b))
☐ Pre-commencement communications pursuant to Ru	le 13e-4(c) under the Exchange Act (17 CFR 2	240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act	:	
Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Title of each class	Trading Symbol(s)	which registered
Units, each consisting of one share of	AEHAU	The NASDAQ Stock
Class A common stock and one half of		Market LLC
one redeemable Warrant		
Class A common stock, par value	AEHA	The NASDAQ Stock
\$0.0001 per share		Market LLC
Warrants, each exercisable for one	AEHAW	The NASDAQ Stock
share of Class A common stock for		Market LLC
\$11.50 per share		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⊠

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

#### Item 8.01. Other Events.

#### Separate Trading of Units, Class A Common Stock and Warrants

On November 3, 2021, Aesther Healthcare Acquisition Corp. (the "Company") announced that, commencing on November 5, 2021, the holders of units ("Units") issued in the Company's initial public offering may elect to separately trade shares of the Company's Class A common stock, par value \$0.0001 per share (the "Class A Common Stock"), and redeemable warrants ("Public Warrants") included in the Units. Each Unit consists of one share of Class A common stock and one half of one Public Warrant, with each whole Public Warrant entitling the holder thereof to purchase one share of Class A Common Stock for \$11.50 per share. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. Units not separated will continue to trade on the Nasdaq Global Market under the symbol "AEHAU." Shares of Class A Common Stock and the Public Warrants will trade on the Nasdaq Global Market under the symbols "AEHA" and "AEHAW," respectively. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the Units into shares of Class A Common Stock and Public Warrants.

A copy of the press release issued by the Company announcing the separate trading of the securities underlying the Units is attached hereto as Exhibit 99.1.

## **Cancellation of Sponsor Shares**

As previously disclosed, our sponsor, Aesther Healthcare Sponsor, LLC (the "Sponsor") owns an aggregate of 2,875,000 shares of our Class B common stock and agreed to cancel up to 375,000 of such shares depending on the extent to which the underwriters' over-allotment option in connection with the Company's initial public offering was exercised. The underwriters' previously exercised a portion (500,000 Units) of the underwriters' option to purchase up to an additional 1,500,000 Units to cover over-allotments, and such over-allotment option has since expired. As such, the Sponsor is in the process of cancelling 250,000 of the Class B common stock originally issued to the Sponsor.

#### Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

## Exhibit

No.	Description
99.1	Press Release, dated November 3, 2021
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 3, 2021

# **Aesther Healthcare Acquisition Corp.**

By: /s/ Suren Ajjarapu

Name: Suren Ajjarapu
Title: Chief Executive Officer



# Aesther Healthcare Acquisition Corp. Announces Separate Trading of its Class A Common Stock and Warrants to Commence on November 5, 2021

**NEW YORK, NY** / **ACCESSWIRE** / **November 3, 2021**— Aesther Healthcare Acquisition Corp. (Nasdaq: AEHAU) (the "<u>Company</u>") today announced that, commencing November 5, 2021, holders of the units sold in the Company's initial public offering may elect to separately trade shares of the Company's Class A common stock and redeemable warrants included in the units.

No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The shares of Class A common stock and redeemable warrants that are separated will trade on the Nasdaq Capital Market under the symbols "AEHA" and "AEHAW," respectively. Those units not separated will continue to trade on the Nasdaq Capital Market under the symbol "AHEAU." Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into shares of Class A common stock and warrants.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on September 14, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

#### **About Aesther Acquisition Corp.**

Aesther Healthcare Acquisition Corp. is a blank-check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus on the pharmaceutical and medical device sectors.

## **Forward Looking-Statements**

This press release contains statements that constitute "<u>forward-looking statements</u>," including with respect to the search for an initial business combination. No assurance can be given that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the Company's initial public offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aesther Healthcare Acquisition Corp. 515 Madison Ave Suite 8078 New York, NY 10022 Attn: Suren Ajjarapu Chairman & CEO suren@aestherhealthcarespac.com (646) 908-2658